# BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

> **NCT07666490** · PHASE4 · RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 644 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation)
- **DRUG:** Foster® 200/6 pMDI (BDP/FF-200/6 µg)

## Key facts

- **NCT ID:** NCT07666490
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-28
- **Primary completion:** 2028-06-13
- **Final completion:** 2028-06-13
- **Target enrollment:** 644 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07666490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07666490, "BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07666490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*